Cell-Penetrating Peptide Delivers Anti-VEGF Eye Drug Without Injections
An eye drop hydrogel using cell-penetrating peptides delivered aflibercept (an anti-VEGF drug) to treat corneal neovascularization, potentially replacing painful eye injections.
Quick Facts
What This Study Found
Cell-penetrating peptide-mediated eye drop hydrogel successfully delivered aflibercept across the corneal barrier, reducing neovascularization without injection.
Key Numbers
Gel 2_1&Eylea showed superior membrane permeability, increased stability, and prolonged drug contact time compared to standard formulations.
How They Did This
Developed CPP-aflibercept eye drop hydrogel formulation. Characterized corneal penetration and drug release. Tested efficacy in corneal neovascularization model.
Why This Research Matters
Eye injections are painful, carry infection risk, and require clinic visits. An eye drop that delivers the same anti-VEGF drugs using peptide technology could transform ophthalmic treatment and improve patient compliance.
The Bigger Picture
Cell-penetrating peptides are enabling non-invasive delivery of drugs that previously required injections. Eye drops represent one of the most patient-friendly applications — if CPPs can reliably deliver anti-VEGF drugs topically, it could expand treatment access for millions with eye diseases.
What This Study Doesn't Tell Us
Preclinical study. Corneal drug delivery does not guarantee reaching the retina for diseases like macular degeneration. CPP-protein stability in eye drop formulations needs long-term evaluation.
Questions This Raises
- ?Could CPP-enhanced eye drops deliver anti-VEGF drugs deep enough for retinal diseases?
- ?How does the efficacy of topical CPP-aflibercept compare to intravitreal injection?
- ?What is the shelf life and stability of CPP-protein eye drop formulations?
Trust & Context
- Key Stat:
- Eye drops replace injections Cell-penetrating peptides enable topical anti-VEGF delivery through eye drops, eliminating the need for painful ocular injections
- Evidence Grade:
- Preliminary evidence: preclinical formulation study demonstrating CPP-enhanced corneal drug delivery. No human clinical data.
- Study Age:
- Published in 2024. Addresses a major unmet need in ophthalmic drug delivery.
- Original Title:
- Aflibercept Loaded Eye-Drop Hydrogel Mediated with Cell-Penetrating Peptide for Corneal Neovascularization Treatment.
- Published In:
- Small (Weinheim an der Bergstrasse, Germany), 20(2), e2302765 (2024)
- Authors:
- Zhou, Jianan, Cai, Yuting(2), Li, Tingting, Zhou, Haixiang, Dong, Huilei, Wu, Xia, Li, Zenghui, Wang, Wenjie, Yuan, Dan, Li, Yun, Shi, Junfeng
- Database ID:
- RPEP-09682
Evidence Hierarchy
Frequently Asked Questions
Could eye drops replace eye injections?
This study shows that cell-penetrating peptides can help large drug molecules cross the corneal barrier when delivered as eye drops. If this approach works in clinical trials, it could replace painful eye injections for conditions like corneal neovascularization.
What role do cell-penetrating peptides play?
The cornea normally blocks large molecules. CPPs act as molecular escorts that help the anti-VEGF drug aflibercept cross this barrier when applied as eye drops, achieving therapeutic drug levels without injection.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09682APA
Zhou, Jianan; Cai, Yuting; Li, Tingting; Zhou, Haixiang; Dong, Huilei; Wu, Xia; Li, Zenghui; Wang, Wenjie; Yuan, Dan; Li, Yun; Shi, Junfeng. (2024). Aflibercept Loaded Eye-Drop Hydrogel Mediated with Cell-Penetrating Peptide for Corneal Neovascularization Treatment.. Small (Weinheim an der Bergstrasse, Germany), 20(2), e2302765. https://doi.org/10.1002/smll.202302765
MLA
Zhou, Jianan, et al. "Aflibercept Loaded Eye-Drop Hydrogel Mediated with Cell-Penetrating Peptide for Corneal Neovascularization Treatment.." Small (Weinheim an der Bergstrasse, 2024. https://doi.org/10.1002/smll.202302765
RethinkPeptides
RethinkPeptides Research Database. "Aflibercept Loaded Eye-Drop Hydrogel Mediated with Cell-Pene..." RPEP-09682. Retrieved from https://rethinkpeptides.com/research/zhou-2024-aflibercept-loaded-eyedrop-hydrogel
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.